Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Accumulated Expenses (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Accumulated Expenses for 4 consecutive years, with $9.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 7.27% to $9.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.4 million through Dec 2025, up 7.27% year-over-year, with the annual reading at $9.4 million for FY2025, 7.27% up from the prior year.
  • Accumulated Expenses hit $9.4 million in Q4 2025 for NewAmsterdam Pharma, up from $5.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $9.4 million in Q4 2025 to a low of $1.1 million in Q1 2024.
  • Historically, Accumulated Expenses has averaged $4.3 million across 4 years, with a median of $3.6 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: soared 157.71% in 2024 and later increased 7.27% in 2025.
  • Year by year, Accumulated Expenses stood at $2.0 million in 2022, then surged by 69.37% to $3.4 million in 2023, then surged by 157.71% to $8.7 million in 2024, then grew by 7.27% to $9.4 million in 2025.
  • Business Quant data shows Accumulated Expenses for NAMS at $9.4 million in Q4 2025, $5.9 million in Q3 2025, and $3.8 million in Q2 2025.